Actively Recruiting
Phase 3 Study to Test the Safety and Effectiveness of CKD-202A SacubitrilValsartan for Treating Essential Hypertension
Led by Chong Kun Dang Pharmaceutical · Updated on 2025-12-11
324
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of CKD-202A SacubitrilValsartan in treating essential hypertension in this Phase 3 randomized, double-blind, active-controlled clinical trial. The study aims to measure changes in mean ambulatory systolic blood pressure over 10 weeks from baseline to assess how well the treatment works and monitor safety. Participants first undergo a 4-week single-blind placebo run-in period where they take placebo doses matching CKD-202A and Valsartan once daily. Following this, a 10-week double-blind treatment period occurs. In one treatment group, participants receive a maintenance dose of CKD-202A with placebo Valsartan another group receives increasing doses of CKD-202A with placebo Valsartan and a control group receives Valsartan. Dosing schedules and placebo tablets vary over the treatment weeks, with participants taking oral doses once daily. During the trial, participants will be regularly assessed for blood pressure changes and safety. The primary outcome is the change in mean ambulatory systolic blood pressure 10 weeks after baseline. Participants will be monitored closely throughout the study to evaluate treatment effects and safety, with the total study duration including screening, run-in, treatment, and follow-up periods as specified by the trial protocol.
CONDITIONS
Brief Title
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Research Team
K
Keehyun Ham, Project Leader
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here